In conclusion, the ATM-Chk2-P53 pathway, CDK2, and CDK4/6 may constitute breakthroughs for which we can develop targeted drugs against the proteins; this is expected to improve the prognosis of patients with malignant tumors. This evidence concerns the gene TP53 and cancer.